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Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with 
reduced risk of breast cancer, though findings have been inconsistent. This inconsistency may 
result from differences in etiology for breast tumors of different subtypes. We examined the 
association between NSAID use and breast cancer characterized by molecular subtypes in a 
population-based case-control study in Western New York. Cases (n=1,170) were women with 
incident, primary, histologically confirmed breast cancer. Controls (n=2,115) were randomly 
selected from NY Department of Motor Vehicles records (<65yrs) or Medicare rolls (≥65yrs). 
Participants answered questions regarding their use of aspirin and ibuprofen in the year prior to 
interview and their use of aspirin throughout their adult life. Logistic regression models 
estimated odds ratios (OR) and 95% confidence intervals (95% CI). Recent and lifetime aspirin 
use was associated with reduced risk, with no differences by subtype. Recent use of ibuprofen 
was significantly associated with increased risk of ER+/PR+ (OR 1.33, 95% CI: 1.09-1.62), 
HER2- (OR 1.27, 95% CI: 1.05-1.53), and p53- breast cancers (OR 1.28, 95% CI: 1.04-1.57), as 
well as luminal A or B breast cancers. These findings support the hypothesis of heterogeneous 











 Chronic inflammation is suspected to be associated with the initiation and promotion of 
carcinogenesis at several anatomic sites, including the breast (1, 2). Epidemiologic studies of  
non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk report inverse 
associations (3, 4), and NSAIDs have demonstrated anti-cancer properties in vitro and in vivo (5-
8), adding further support to this hypothesis.  
 There is evidence that biologically distinct subtypes of breast cancer, distinguished on the 
basis of gene expression (9-11) or tumor marker expression (12), may also be etiologically 
distinct (13-16). Epidemiologic studies of the association of NSAIDs with breast cancer 
characterized by ER or PR status have been inconsistent (17-28). However, no previous studies 
have reported on the association of NSAID use with breast cancer risk according to HER2 
protein expression, p53 mutation status, or joint ER, PR, and HER2 status.  
 We reported previously that recent and lifetime use of aspirin but not recent use of 
ibuprofen was inversely associated with breast cancer risk (29). In light of potential differences 
in breast cancer etiology for breast cancer classified by these subtypes, here we build upon our 
previous report and examine the associations of aspirin and ibuprofen use with risk of breast 
cancer subtypes defined by molecular characteristics in the Western New York Exposures and 
Breast Cancer (WEB) study.  
Materials & Methods 
  The WEB study is a population-based case-control study of women living in Erie and 
Niagara counties of western New York State. Study methods have been described elsewhere 
(29). Briefly, cases and controls were identified between 1996 and 2001. Women were eligible to 
participate in the study if they were between the ages of 35 and 79 years, spoke English, had no 
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prior history of cancer other than non-melanoma skin cancer, and were current residents of Erie 
or Niagara counties. Cases were women with incident, first primary, histologically-confirmed 
breast cancer. Nurse case-finders who visited pathology departments of area hospitals identified 
potential cases. Patients’ physicians were contacted to verify the diagnosis and to obtain 
permission to contact them. Once permission was granted, cases were interviewed within one 
year of diagnosis. Most cases were interviewed within 6 months (median 5.4 months). Controls 
were randomly selected from Department of Motor Vehicles records (<65yrs) or Medicare rolls 
(≥65yrs) and frequency matched to cases on age and race. Seventy-two percent of eligible cases 
(n=1,170) and 63% of eligible controls (n=2,115) were interviewed. Among those that provided 
a reason for non-participation, the primary reasons among eligible cases were physician refusal 
for permission to contact or patient disinterest; among eligible controls, the primary reasons were 
scheduling conflicts or illness. All participants provided informed consent and study protocols 
were approved by the Institutional Review Boards of the University at Buffalo and participating 
hospitals. 
Data Collection 
 Trained interviewers conducted computer-assisted, in-person interviews and participants 
completed an extensive self-administered questionnaire. Participants were queried regarding 
breast cancer risk factors including medical and reproductive history. In particular, participants 
were asked to report their average monthly frequency of aspirin, ibuprofen, and acetaminophen 
use in the 12-24 months prior to interview and the average number of pills taken per day during 
that time period (“intensity”). Additionally, participants were asked about their average monthly 
frequency of aspirin use for each decade of adult life beginning at age 21.  
5 
 
 Women were classified according to their reported frequency of aspirin and ibuprofen use 
as non-users (0 days/month), infrequent users (≤14 days/month), or regular users (>14 
days/month). Intensity was categorized as non-use (0 pills/day), low intensity (<2 pills/day) and 
high intensity (≥2 pills/day). The high category cut-point of NSAID frequency and intensity was 
determined using the highest tertile of aspirin use among controls. From data on adult lifetime 
aspirin use, participants were classified based upon their average monthly aspirin use throughout 
their adult lifetime [non-users (0 days/month), irregular users (≤10 days/month), regular users 
(>10 days/month)]. 
Biological Specimens 
 Archived tumor blocks were obtained for 922 (79%) of cases. ER and PR status was 
determined by a single pathologist using immunohistochemistry (IHC) as described by Allred et 
al (30). For patients for whom tumor blocks were unavailable or for whom hormone receptor 
status was unable to be determined (e.g., insufficient tumor tissue) (n=222), hormone receptor 
status was obtained from hospital chart review. We compared results of our assessment with 
medical chart assignment of ER and PR status among participants for whom we had data from 
both sources (ER: n=682, PR: n=668); values were in good agreement (ER: κ=0.66, PR: κ=0.73). 
Using both methods, ER status was determined for 91% (n =752 ER+ and 315 ER-) and PR 
status for 90% (n=656 PR+ and 392 PR-) of cases. 
 HER2 protein expression was determined in a manner similar to that for ER and PR 
status. A single pathologist determined HER2 expression for each sample using IHC. HER2 was 
scored using the guidelines of HerceptTestTM. We classified tumors with scores 0-2+ (negative-
equivocal) as HER2-negative (HER2-) and tumors with a score of 3+ (strongly positive) as 
HER2-positive (HER2+). A HER2 score of 2+ (equivocal) was determined by IHC for 31 cases 
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and classified as HER2-. For patients for whom HER2 expression could not be determined 
(n=111), this data was obtained from patients’ hospital charts. Among participants for whom we 
had data from both sources (n=285), values were in good agreement (κ=0.65). HER2 expression 
data were available from one source or the other for 64% (n=74 HER2+ and 677 HER2-) of 
cases.   
 P53 mutation status was determined from tumor blocks using the Affymetrix p53 
Genechip System (Santa Clara, CA), which consists of a multiplex PCR amplification of exons 
2-11 of the p53 gene , followed by hybridization of the PCR product on the array. All mutation 
calls from the array data were confirmed by direct sequencing. This method has been previously 
described in detail (31). Data were available for 63% (n=205 p53+ and 528 p53-) cases. 
Statistical Analysis 
 We classified breast cancer cases into subtypes according to ER/PR, HER2, and p53 
status, and by joint combinations of ER, PR, and HER2 (10, 12). Luminal-like cases were ER+ 
or PR+ and HER2- (luminal A, n=540) or HER2+ (luminal B, n=39). HER2 expressing tumors 
were defined as ER-/PR- and HER2+ (n=34). There were 134 triple-negative (ER-/PR-/HER2-) 
cases.  
We used unordered polytomous logistic regression models to estimate multivariable-
adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for the association of recent 
NSAID use and lifetime aspirin use with breast cancer stratified by molecular subtypes. P-values 
for heterogeneity (P-heterogeneity) of the OR between breast cancer subtypes were calculated 
using adjusted unconditional (2 case groups) or polytomous logistic regression (≥3 case groups) 
models. Exposure-response trends were calculated with logistic regression models from beta-
coefficients of NSAID frequency and intensity. All reported P-values are two-tailed and α=0.05.  
7 
 
 We considered as potential confounders in multivariable modeling known and suspected 
risk factors for breast cancer including age, education, age at menarche, age at first, birth, parity, 
body mass index (BMI) [measured, kg/m2], lifetime physical activity [sports or exercise; 
hours/week], menopausal status, postmenopausal hormone use, family history of breast cancer, 
and history of benign breast disease. We also assessed potential confounding by correlates of 
NSAID use, including histories of hypertension, arthritis, or cerebrovascular disease. We 
adjusted models for the frequency matching variables (age and race) and years of education and 
menopausal status. The remaining factors did not alter point estimates by ≥10% and were 
excluded from final models. Thus, final multivariable models were adjusted for age (years), 
years of education, race (white/non-white), and menopausal status 
(premenopausal/postmenopausal), and were simultaneously adjusted for use of other NSAIDs. 
Regression models were run among 1,111 (95%) cases and 2,052 (97%) controls with complete 
data on exposure and adjustment variables.  
Results   
 Characteristics of the WEB study population have been described previously (29). The 
associations of NSAID use with breast cancer stratified by joint-ER and PR status are given in 
Table 1. Recent aspirin use was associated with reductions in breast cancer risk across cases 
groups, regardless of frequency or intensity of use; however with the exception of ER-/PR+ 
cancers, findings were not statistically significant and no exposure-response gradient was 
observed for frequency or intensity of use. In contrast, compared to non-users, recent ibuprofen 
users had a statistically significant 33% increased risk of ER+/PR+ breast cancer (OR 1.33, 95% 
CI: 1.09-1.62) but not ER+/PR-, ER-/PR+, or ER-/PR- breast cancers. For ibuprofen use versus 
non-use, differences across subtypes were not statistically significant, with the exception that the 
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P-heterogeneity of the OR for ER+/PR+ vs. ER-/PR- was 0.02. For ER+/PR+ breast cancer, 
point estimates were also elevated for increasing frequency (>14 days/month: OR 1.23, 95% CI: 
0.85-1.77; P-trend=0.31), and intensity of ibuprofen use (≥2 pills/day: OR 1.32, 95% CI: 1.06-
1.63; P-trend=0.38). These findings were also statistically different than those of ER-/PR- breast 
cancer (P-heterogeneity=0.04 and 0.02, respectively); however the p-trend for frequency or 
intensity of use of ibuprofen among ER+/PR+ breast cancers did not achieve statistical 
significance. In a sensitivity analysis, comparing users to non-users of aspirin and ibuprofen, 
respectively, results were unchanged when ER and PR were examined separately and there were 
no differences when stratified on menopausal status (data not shown). 
 Associations of recent NSAID use with breast cancer stratified by HER2 expression 
status are given in Table 2. Associations with aspirin use did not differ by HER2 status. 
Compared to non-use, aspirin use was associated with reduced risks of HER2+ (OR 0.84, 95% 
CI: 0.52-1.36) and HER2- breast cancers (OR 0.91, 95% CI: 0.76-1.09) (P-heterogeneity=0.76). 
Again, there was no clear exposure-response gradient with increasing frequency or intensity of 
aspirin use. Use of ibuprofen in the previous year was associated with a statistically significant 
27% increased risk of HER2- breast cancers (OR 1.27, 95% CI: 1.05-1.53) and was not 
associated with HER2+ breast cancers (OR 0.83, 95% CI: 0.51-1.35). Compared to non-use, 
categories of ibuprofen frequency and intensity were associated with elevated risks of HER2- 
tumors, however the association was strongest amongst infrequent users (≤14 days/ month: OR 
1.28, 95% CI: 1.05-1.56) rather than frequent users (>14 days/month: OR 1.11, 95% CI: 0.78-
1.58) and low intensity of use (<2 pills/day: OR 1.36, 95% CI: 1.04-1.80) rather than high (≥2 
pills/day: OR 1.21, 95% CI: 0.99-1.48) giving no evidence of an exposure-response gradient. 
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 Similar to our findings of aspirin use with breast cancer stratified by ER/PR or HER2, 
separately, we observed no clear differences in the associations of aspirin use with breast cancer 
characterized by combinations of ER, PR, and HER2 (Table 3). There was a suggestion of an 
increased risk of luminal B tumors and a large inverse association for HER2 expressing tumors, 
although confidence intervals were very wide and the findings were not statistically different. 
However, use of ibuprofen was associated with 34-40% increased risks of luminal A (OR 1.34, 
95% CI: 1.09-1.65) and luminal B (OR 1.41, 95% CI: 0.69-2.87) breast cancer. Risks of these 
subtypes were similarly elevated for the highest categories of frequency and intensity of 
ibuprofen use. Use of ibuprofen was suggestive of a 50% reduction in risk of HER2 expressing 
tumors (OR 0.50, 95% CI: 0.25-1.02), although not statistically significant. The P-heterogeneity 
compared to the luminal A subtype was <0.01. The highest categories of frequency (>14 
days/month: OR 0.43, 95% CI: 0.10-1.89) and intensity of use (≥2 pills/day: OR 0.42, 95% CI: 
0.19-0.94) were associated with similar reductions in risk of HER2 expressing breast cancer. 
This latter association was significantly different than for the luminal A subtype (P-
heterogeneity<0.01). Ibuprofen use was not associated with risk of triple-negative breast cancer 
(OR 0.99, 95% CI; 0.68-1.45). 
 We observed no significant differences in risk by p53 status associated with aspirin use 
(Table 4). Recent ibuprofen use was not associated with p53+ tumors (OR 0.96, 95% CI: 0.71-
1.31), while it was positively associated with risk of p53- tumors (OR 1.28, 95% CI: 1.04-1.57). 
However, point estimates were not statistically different (P-heterogeneity=0.11) and we observed 




 Analyses of the associations of adult lifetime aspirin use with breast cancer stratified by 
breast cancer subtypes were limited by small numbers for several case groups (Supplemental 
Table). We did find that women who used aspirin regularly throughout their adult life had similar 
reduction of risk of breast cancers defined by either ER or PR. The strongest finding was for ER-
/PR- tumors. Regular use was associated with a 48% reduction in risk of this subtype (OR 0.52, 
95% CI: 0.24-1.14), albeit based upon 8 exposed cases. Although the finding was not statistically 
different than that of ER+/PR+ (P-heterogeneity=0.36), there was evidence of a significant trend 
(P-trend=0.02). Lifetime aspirin use was also similarly associated with significant reductions in 
risks of HER2- (OR 0.60, 95% CI: 0.38-0.95; P-trend=0.04) and p53- (OR 0.56, 95% CI: 0.33-
0.95; P-trend=0.02) breast cancers; however the point-estimates were not statistically different 
than those for HER2+ (P-heterogeneity=0.20) or p53+ tumors (P-heterogeneity=0.48). Regular 
lifetime aspirin use was associated with a 41% reduction in risk of luminal A breast cancer (OR 
0.59, 95% CI: 0.36-0.97; P-trend=0.05) and a statistically non-significant 48% reduction in risk 
of triple-negative breast cancer (OR 0.52, 95% CI: 0.18-1.54; P-trend=0.26). There was no clear 
association of lifetime aspirin with either the luminal B or HER2 expressing phenotypes. 
Discussion 
 In this study population of women living in Western New York, we previously found that 
recent use of aspirin but not ibuprofen was inversely associated with breast cancer risk (29). We 
found here that, for aspirin, this association did not differ by molecular subtype. For ibuprofen, 
recent use was associated with an increased risk of breast cancer defined as ER+/PR+, HER2-, 
p53- or luminal A/B, and a decreased risk of HER2 expressing tumors. With few exceptions, we 
observed no statistically significant exposure-response gradients for increasing frequency or 
intensity of aspirin or ibuprofen use in association with any molecular subtype. Similar to our 
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findings with recent aspirin use, aspirin use during a woman’s adult lifetime was associated with 
similar reductions in risks for most tumor subtypes. 
Because COX-2 expression has been associated in vitro with estrogen synthesis (7, 8), we 
hypothesized that NSAID use would be inversely associated with risk of hormone receptor 
positive tumors. Authors of several case-control (18, 21, 22) and cohort studies (17, 19, 20, 23, 
24, 27), and one randomized controlled trial (26, 28), have examined the association of NSAID 
use and breast cancer stratified by hormone receptor status; however findings have been 
inconsistent (17-28). Because previous studies have reported associations using different 
combinations of ER/PR expression status (e.g., ER+/PR+ and ER-/PR-), or ER and PR status 
separately, comparisons between our findings and others are challenging. Comparisons are 
further limited in that not all studies report associations for individual NSAIDs, assuming equal 
effects of this broad class of medications. In this study, aspirin use was associated with reduced 
risks of breast characterized by joint ER/PR status. Several others have reported similar findings 
(18, 24, 27). In a recent analysis of the Iowa Women’s Health Study, Bardia et al. (27), reported 
that ever aspirin use was associated with similar reductions in risk for ER+ (RR 0.77, 95% CI: 
0.67-0.89), ER- (RR 0.78, 95% CI: 0.56-1.08), PR+ (RR 0.79, 95% CI: 0.68-0.92), and PR- (RR 
0.73, 95% CI: 0.56-0.95) tumors; similar reductions in risk were observed when ER and PR were 
combined. In contrast, others have observed reduced risks of hormone receptor positive (i.e., 
ER+, ≥1 positive hormone receptor, or ER+/PR+) breast cancer only (21-23), increased risks of 
hormone receptor negative breast cancers (19), or no association (17, 20). In a randomized 
controlled trial of low-dose (100mg) aspirin taken every other day for 10 years compared to a 
placebo, there was no association with breast cancer risk overall (26) or with breast cancer 
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defined by ER or PR (28). It is widely speculated, however, that this dose may be too low for 
chemoprevention (28). 
 In contrast to our hypothesis, we observed increased risks of ER+/PR+ breast cancer in 
association with recent ibuprofen use. Several others have observed similar results. In the 
Multiethnic Cohort Study, there was an increase in hormone receptor positive breast cancer 
among women who were recent, short-term (≤1 year) users of  non-aspirin NSAIDs compared to 
non-users (HR 1.29, 95% CI: 1.02-1.63), and no association among women with hormone 
receptor negative tumors (HR 1.06, 95% CI: 0.73-1.53), although greater duration of use at 
baseline was inversely associated with risk of hormone receptor positive tumors (17). In the 
California Teachers Study, daily ibuprofen use was associated with increased breast cancer risk 
that did not differ by ER and PR status (19), and in the Nurse’s Health Study II cohort of 
premenopausal women, non-aspirin NSAID use 2-3 times per week was associated with 
increased breast cancer risk (RR 1.37, 95% CI: 1.09-1.67), with no difference by hormone 
receptor status (25). Our observation of inverse associations of breast cancers defined by ER and 
PR with aspirin use and an increased risk of hormone receptor positive tumors with ibuprofen 
use are inconsistent with our hypothesis that inhibition of COX-2 through the use of NSAIDs 
would result in the strongest reduction in risk of hormone receptor positive tumors. 
  This study is the first, to our knowledge, to report on the association of NSAID use with 
breast cancer characterized by HER2 expression, p53 mutation status, or combinations of ER, 
PR, and HER2. We found no difference in the association of aspirin use with tumors 
characterized by HER2 or p53, and use of ibuprofen was associated with increased risks of 
HER2- and p53- breast cancers. We know of only two other reports of the association of 
NSAIDs with any cancer characterized by p53 status and no others of breast cancer (32, 33). 
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Freedman et al. (33), reported no differences in the association of aspirin use with colon cancer 
stratified by p53 expression. Figueroa et al. (32), reported no differences in the association of 
aspirin or any NSAID with esophageal or gastric cancers by p53 status in a population-based 
case-control study. Nevertheless, our findings suggest further investigations are needed.  
 The primary strength of this report is that it is the first to comprehensively examine the 
association of NSAIDs, and use of aspirin during a woman’s adult lifetime, with breast cancer 
subtypes defined by ER, PR, HER2, and p53. An additional strength is our ability to measure of 
the frequency and intensity of use of aspirin and ibuprofen. 
This study also has several important limitations. Foremost, we were limited in power to 
detect differences between rare breast cancer subgroups. Our findings nevertheless merit further 
investigation. In addition, our classification of subtypes based on ER, PR, and HER2 is a 
surrogate for a more comprehensive nomenclature determined by tumor marker expression (12); 
therefore the subtypes defined in this study, particularly the differences between luminal A and B 
tumors, may be misclassified. Because fluorescence in situ hybridization was not performed to 
validate tumors with an equivocal (i.e., 2+) HER2 score, and the agreement between IHC and 
medical records was good but not excellent, misclassification of HER2 status is possible. In 
addition, data collected on recent NSAID use were limited to frequency and intensity of use and 
information on NSAID dose, duration, or indication for use was not collected. Our classification 
of infrequent and regular users may misclassify participants who were regular users at an earlier 
time. However it is unlikely that such misclassification would differ by disease status or case 
group and would likely result in a bias of point estimates towards the null and widening of 
confidence intervals (34). Doses of aspirin and ibuprofen made available over the counter and by 
prescription vary substantially; the absence of exposure-response gradients may be because of 
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measurement error related to the lack of dose data. It is also possible that our results may be 
confounded by other unmeasured factors, in particular by the indication for NSAID use or use of 
other NSAIDs such as naproxen or selective COX-2 inhibitors such as celecoxib. However, 
adjustment for history of arthritis, hypertension, diabetes, or cerebrovascular disease had no 
effect on point estimates. Additionally, for analyses of adult lifetime aspirin, we were unable to 
assess confounding by an overall healthy lifestyle. As with any case-control study, possible 
effects of recall bias need to be considered, although it is unlikely that participants would differ 
in their ability to recall their NSAID exposure depending upon the molecular classification of 
their cancer. It is possible that our findings may be due, in part, to self-selection into the study. 
Though unlikely, if selection into the study was based upon use of aspirin or ibuprofen or some 
correlate of their use, our findings could be biased. Again, it is unlikely that that this bias would 
differ by tumor characteristics. Comparing cases with tumors blocks vs. those without, use of 
aspirin and ibuprofen was similar. 
NSAIDs are thought to exhibit their anti-inflammatory and chemopreventive effects by 
non-selectively binding to the cyclooxygenase enzymes (COX-1 & 2; EC 1.14.99.1), which 
catalyze the synthesis of pro-inflammatory prostaglandins from arachidonic acid (35). Among 
the prostaglandins, prostaglandin E2 is considered a powerful mitogen and potential 
chemopreventive target (35, 36). PGE2 has been shown to induce aromatase expression and de 
novo estrogen synthesis in breast epithelia and stromal cells in vitro; introduction of NSAIDs has 
been shown to reduce estrogen levels in a dose-dependent manner (8). In humans, the association 
of NSAIDs with circulating estrogen levels has been inconsistent (37-39). We know of no 
mechanism, however, by which ibuprofen would increase risk of breast cancer subtypes. 
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 There is limited evidence that COX-2 expression is correlated with ER, PR, HER2, and 
p53 expression in breast tumors (40-44). Findings of in vitro studies among human invasive 
breast cancer cells suggest that HER2 oncogene activation regulates COX-2 expression in breast 
cancer (43, 45, 46), inducing a positive feedback loop in which PGE2 in turn further induces 
HER2 expression (47). Introduction of an NSAID has been shown to reduce HER2 expression 
(47). P53 may also be associated with COX-2 expression in vitro (48, 49) and animal models of 
breast cancer give limited evidence that p53 expression is associated with COX-2 expression (43, 
50).  
The findings of this large, population-based case-control study support existing evidence 
that aspirin is inversely associated with breast cancer risk. Our findings do not support, however, 
the hypothesis that aspirin’s effects are differential by tumor subtype. Use of ibuprofen may be 
associated with increased risk of certain breast cancer subtypes associated with less aggressive 
phenotype and inversely associated with the risk of the aggressive HER2 expressing phenotype. 
Our findings provide preliminary evidence to suggest that aspirin and ibuprofen are 
heterogeneous in their effects, and lend further support to the hypothesis that the etiology of 
breast tumors differs by subtype. Epidemiologic studies of the association of NSAIDs with breast 
tumors characterized by molecular subtype should include detailed information of the timing and 
dose of a wide range of individual prescription and non-prescription NSAIDs. A better 
understanding of inflammation in relation to risk of breast cancer could significantly advance 
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n = 590,  
n (%) 
ER+/PR-  
n = 150,  
n (%) 
ER-/PR+  
n = 66,  
n (%) 
ER-/PR-  
n = 241,  
n (%) 
Controls 




OR (95% CI)a 
ER+/PR- 
v. Controls 
OR (95% CI)a 
ER-/PR+ 
v. Controls 
OR (95% CI)a 
ER-/PR- 
v. Controls 
OR (95% CI)a 
Aspirin          
 Non-Users  331 (56.68) 80 (54.42) 46 (70.77) 146 (60.83) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Users 253 (43.32) 67 (45.58) 19 (29.23) 94 (39.17) 957 (45.70) 0.86 (0.71-1.04) 0.88 (0.61-1.25) 0.57 (0.33-0.98) 0.80 (0.60-1.05) 
Frequency          
 Non-Users 331 (56.68) 80 (54.42) 46 (70.77) 146 (60.83) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 171 (29.28) 40 (27.21) 13 (20.00) 71 (29.58) 665 (31.76) 0.86 (0.69-1.06) 0.77 (0.51-1.17) 0.51 (0.27-0.96) 0.83 (0.61-1.12) 
 Regular Users (>14 days/month) 82 (14.04) 27 (18.37) 6 (9.23) 23 (9.58) 292 (13.94) 0.84 (0.63-1.13) 1.10 (0.66-1.82) 0.73 (0.30-1.80) 0.67 (0.41-1.08) 
     P-trend 0.33 0.67 0.47 0.12 
Intensity          
 Non-Users 331 (56.68) 80 (54.05) 46 (69.70) 146 (60.83) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 121 (20.58) 42 (28.38) 9 (13.64) 43 (17.92) 414 (19.75) 0.94 (0.73-1.21) 1.26 (0.82-1.92) 0.65 (0.30-1.40) 0.92 (0.63-1.35) 
 High (≥2 pills/day) 136 (23.13) 26 (17.57) 11 (16.67) 51 (21.25) 545 (26.00) 0.83 (0.66-1.05) 0.60 (0.37-0.97) 0.54 (0.28-1.07) 0.71 (0.51-1.00) 
     P-trend 0.39 0.02 0.05 0.11 
Ibuprofen           
 Non-Users 237 (40.44) 67 (46.53) 27 (41.54) 108 (45.38) 953 (45.62) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Users 349 (59.56) 77 (53.47) 38 (58.46) 130 (54.62) 1,136 (54.38) 1.33 (1.09-1.62) 1.10 (0.76-1.58) 0.97 (0.57-1.65) 0.93 (0.70-1.24)* 
Frequency          
 Non-Users 237 (40.44) 67 (46.53) 27 (41.54) 108 (45.38) 953 (45.62) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 298 (50.85) 65 (45.14) 34 (52.31) 116 (48.74) 963 (46.10) 1.35 (1.09-1.66) 1.10 (0.75-1.60) 1.00 (0.58-1.73) 0.99 (0.74-1.33)* 
 Regular Users (>14 days/month) 51 (8.70) 12 (8.33) 4 (6.15) 14 (5.88) 173 (8.28) 1.23 (0.85-1.77) 1.04 (0.53-2.04) 0.77 (0.26-2.27) 0.62 (0.34-1.13)* 
     P-trend 0.31 0.73 0.66 0.27 
Intensity          
 Non-Users 237 (40.44) 67 (45.58) 27 (41.54) 108 (45.38) 953 (45.62) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 84 (14.43) 24 (16.33) 14 (21.54) 32 (13.39) 284 (13.54) 1.28 (0.95-1.72) 1.21 (0.73-2.03) 1.41 (0.70-2.82) 1.01 (0.65-1.56) 
 High (≥2 pills/day) 261 (44.85) 56 (38.10) 24 (36.92) 99 (41.42) 860 (41.01) 1.32 (1.06-1.63) 1.02 (0.69-1.52) 0.77 (0.43-1.38) 0.91 (0.67-1.24)* 
     P-trend 0.38 0.62 0.51 0.89 
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; ER, estrogen receptor; PR, progesterone receptor; OR, odds ratio; CI, confidence interval 
* P-heterogeneity < 0.05 for comparisons of ORs in each breast cancer subtype versus ER-/PR- 
















n = 74, n (%) 
 
HER2- Cases 
n = 677, n (%) 
 
Controls 
n = 2,115, n (%) 
HER2+  
v. Controls 
OR (95% CI)a 
HER2-  
v. Controls 
OR (95% CI)a 
Aspirin      
 Non-Users  45 (60.81) 373 (55.75) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 
 Users 29 (39.19) 296 (44.25) 957 (45.70) 0.84 (0.52-1.36) 0.91 (0.76-1.09) 
Frequency      
 Non-Users 45 (60.81) 373 (55.75) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 19 (25.68) 206 (30.79) 665 (31.76) 0.75 (0.43-1.31) 0.91 (0.74-1.11) 
 Regular Users (>14 days/month) 10 (13.51) 90 (13.45) 292 (13.94) 1.19 (0.58-2.48) 0.87 (0.58-2.48) 
   P-trend 0.27 0.21 
Intensity      
 Non-Users 45 (60.81) 373 (55.42) 1,137 (54.25) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 18 (24.32) 140 (20.80) 414 (19.75) 1.55 (0.84-2.84) 0.97 (0.76-1.24) 
 High (≥2 pills/day) 11 (14.86) 160 (23.77) 545 (26.00) 0.50 (0.25-0.98) 0.88 (0.70-1.09) 
   P-trend 0.18 0.08 
Ibuprofen       
 Non-Users 32 (32.24) 275 (41.11) 953 (45.62) 1.00 (reference) 1.00 (reference) 
 Users 52 (56.76) 394 (58.89) 1,136 (54.38) 0.83 (0.51-1.35) 1.27 (1.05-1.53) 
Frequency      
 Non-Users 32 (32.24) 275 (41.11) 953 (45.62) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 34 (45.95) 339 (50.67) 963 (46.10) 0.81 (0.48-1.36) 1.28 (1.05-1.56) 
 Regular Users (>14 days/month) 8 (10.81) 55 (8.22) 173 (8.28) 1.03 (0.46-2.32) 1.11 (0.78-1.58) 
   P-trend 0.21 0.79 
Intensity      
 Non-Users 32 (43.24) 275 (41.11) 953 (45.45) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 15 (20.27) 106 (15.84) 284 (13.54) 1.27 (0.66-2.44) 1.36 (1.04-1.80) 
 High (≥2 pills/day) 27 (36.49) 288 (43.05) 860 (41.01) 0.68 (0.39-1.17) 1.21 (0.99-1.48)* 
   P-trend 0.12 0.31 
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio; CI, confidence interval 
* P-heterogeneity < 0.05 for comparisons of HER2- versus HER2+ ORs 


























n = 134,  
n (%)  
 
Controls 





OR (95% CI)b 
 
Luminal B  
v. Controls 








OR (95% CI)b 
Aspirin Use          
 Non-Users  291 (54.60) 20 (51.28) 24 (70.59) 80 (60.15) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Users 242 (45.40) 19 (48.72) 10 (29.41) 53 (39.85) 957 (45.70) 0.93 (0.77-1.14) 1.29 (0.68-2.47) 0.52 (0.24-1.13) 0.82 (0.56-1.18) 
Frequency          
 Non-Users 291 (54.60) 20 (51.28) 24 (70.59) 80 (60.15) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 166 (31.14) 14 (35.90) 5 (14.71) 40 (30.08) 665 (31.76) 0.93 (0.75-1.17) 1.28 (0.63-2.58) 0.36 (0.14-0.97) 0.85 (0.57-1.27) 
 Regular Users (>14 days/month) 76 (14.26) 5 (12.82) 5 (14.71) 13 (9.77) 292 (13.94) 0.92 (0.68-1.25) 1.51 (0.54-4.24) 1.02 (0.37-2.83) 0.66 (0.35-1.26) 
 P-trend      0.44 0.20 0.71 0.17 
Intensity          
 Non-Users 291 (54.19) 20 (51.28) 24 (70.59) 80 (60.15) 1,137 (54.25) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 116 (21.60) 12 (30.77) 6 (17.65) 23 (17.29) 414 (19.75) 1.00 (0.77-1.30) 2.63 (1.18-5.86)* 0.87 (0.33-2.27) 0.87 (0.52-1.44) 
 High (≥2 pills/day) 130 (24.21) 7 (17.95) 4 (11.76) 30 (22.56) 545 (26.00) 0.91 (0.72-1.16) 0.72 (0.30-1.73) 0.34 (0.12-0.98) 0.78 (0.50-1.20) 
 P-trend      0.15 0.61 0.18 0.27 
Ibuprofen Use          
 Non-Users  215 (40.26) 12 (30.77) 19 (55.88) 59 (44.70) 953 (45.62) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Users 319 (59.74) 27 (69.23) 15 (44.12) 73 (55.30) 1,136 (54.38) 1.34 (1.09-1.65) 1.41 (0.69-2.87) 0.50 (0.25-1.02)* 0.99 (0.68-1.45) 
Frequency          
 Non-Users 215 (40.26) 12 (30.77) 19 (55.88) 59 (44.70) 953 (45.62) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 270 (50.56) 21 (53.85) 13 (38.24) 67 (50.76) 963 (46.10) 1.34 (1.09-1.66) 1.27 (0.60-2.68) 0.55 (0.26-1.17)* 1.08 (0.73-1.60) 
 Regular Users (>14 days/month) 49 (9.18) 6 (15.38) 2 (5.88) 6 (4.55) 173 (8.28) 1.30 (0.89-1.89) 2.17 (0.78-6.04) 0.43 (0.10-1.89) 0.54 (0.23-1.29) 
 P-trend      0.29 0.05 0.88 0.13 
Intensity          
 Non-Users 215 (40.34) 12 (30.77) 19 (55.88) 59 (44.36) 953 (45.45) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 88 (16.51) 10 (25.64) 5 (14.71) 18 (13.53) 284 (13.54) 1.45 (1.07-1.95) 2.10 (0.87-5.11) 0.76 (0.27-2.14) 1.10 (0.62-1.94) 
 High (≥2 pills/day) 230 (43.15) 17 (43.59) 10 (29.41) 56 (42.11) 860 (41.01) 1.28 (1.02-1.60) 1.16 (0.53-2.53) 0.42 (0.19-0.94)* 0.97 (0.65-1.45) 
 P-trend      0.36 0.75 0.07 0.60 
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; ER, estrogen receptor; PR, progesterone receptor; OR, odds ratio; CI, confidence interval 
* P-heterogeneity < 0.05 for comparisons of ORs in each breast cancer subtype versus Luminal A 
a  Luminal A: ER+ or PR+, HER2-; Luminal B: ER+ or PR+, HER2+; HER2 Expressing: ER-/PR-, HER2+; Triple-negative: ER-/PR-/HER2-  















n = 205, n (%) 
 
P53- Cases 
n = 528, n (%) 
 
Controls 
n = 2,115, n (%) 
P53+ 
v. Controls 
OR (95% CI)a 
P53- 
v. Controls 
OR (95% CI)a 
Aspirin      
 Non-Users  117 (58.21) 305 (58.54) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 
 Users 84 (41.79) 216 (41.46) 957 (45.70) 0.82 (0.61-1.12) 0.82 (0.67-1.01) 
Frequency      
 Non-Users 117 (58.21) 305 (58.54) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 58 (28.86) 150 (28.79) 665 (31.76) 0.81 (0.58-1.14) 0.82 (0.65-1.02) 
 Regular Users (>14 days/month) 26 (12.94) 66 (12.67) 292 (13.94) 0.81 (0.49-1.33) 0.82 (0.60-1.13) 
   P-trend 0.46 0.26 
Intensity      
 Non-Users 117 (58.21) 305 (58.54) 1,137 (54.30) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 38 (18.81) 104 (19.81) 414 (19.75) 0.88 (0.58-1.34) 0.94 (0.72-1.23) 
 High (≥2 pills/day) 47 (23.27) 116 (22.10) 545 (26.00) 0.83 (0.58-1.19) 0.75 (0.59-0.96) 
   P-trend 0.42 0.02 
Ibuprofen       
 Non-Users 91 (44.83) 208 (40.00) 953 (45.62) 1.00 (reference) 1.00 (reference) 
 Users 112 (55.17) 312 (60.00) 1,136 (54.38) 0.96 (0.71-1.31) 1.28 (1.04-1.57) 
Frequency      
 Non-Users 91 (44.83) 208 (40.00) 953 (45.62) 1.00 (reference) 1.00 (reference) 
 Infrequent Users (≤14 days/month) 99 (48.77) 265 (50.96) 963 (46.10) 1.01 (0.73-1.40) 1.28 (1.03-1.59) 
 Regular Users (>14 days/month) 13 (6.40) 47 (9.04) 173 (8.28) 0.70 (0.36-1.34) 1.22 (0.84-1.77) 
   P-trend 0.93 0.40 
Intensity      
 Non-Users 91 (44.83) 208 (40.00) 953 (45.62) 1.00 (reference) 1.00 (reference) 
 Low (<2 pills/day) 23 (11.33) 80 (15.38) 284 (13.54) 0.78 (0.48-1.28) 1.37 (1.01-1.86) 
 High (≥2 pills/day) 89 (43.84) 232 (44.62) 860 (41.01) 1.00 (0.72-1.40) 1.23 (0.98-1.53) 
   P-trend 0.61 0.45 
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio; CI, confidence interval 
* P-heterogeneity < 0.05 for comparisons of p53- versus p53+ ORs  







Supplemental Table. Associations of lifetime aspirin use with subsets of breast cancer, among WEB study participants. 
 Lifetime Aspirin  
 Non-users  Irregular Users 
(≤10 days/month) 
















OR (95% CI)b 
 
P-trend 
          
ER+/PR+ vs. Controls 112/369 1.00 (reference)  424/1,554 0.85 (0.66-1.08)  34/138 0.74 (0.48-1.16) 0.23 
ER+/PR- vs. Controls 25/369 1.00 (reference)  109/1,554 0.88 (0.55-1.39)  9/138 0.63 (0.27-1.50) 0.29 
ER-/PR+ vs. Controls 12/369 1.00 (reference)  50/1,554 1.20 (0.63-2.32)  2/138 0.55 (0.12-2.52) 0.18 
ER-/PR- vs. Controls 45/369 1.00 (reference)  178/1,554 1.03 (0.72-1.47)  8/138 0.52 (0.24-1.14) 0.02 
          
HER2+ vs. Controls 11/369 1.00 (reference)  55/1,554 1.50 (0.77-2.94)  5/138 1.44 (0.48-4.28) 0.55 
HER2- vs. Controls 124/369 1.00 (reference)  499/1,554 0.93 (0.73-1.17)  32/138 0.60 (0.38-0.95) 0.04 
          
Luminal A 101/369 1.00 (reference)  398/1,554 0.88 (0.68-1.14)  27/1,554 0.59 (0.36-0.97) 0.05 
Luminal B 6/369 1.00 (reference)  28/1,554 1.47 (0.59-3.66)  3/1,554 1.62 (0.39-6.72) 0.92 
HER2 Expressing 5/369 1.00 (reference)  26/1,554 1.48 (0.55-3.94)  2/1,554 1.25 (0.24-6.60) 0.38 
Triple-negative 23/369 1.00 (reference)  99/1,554 1.11 (0.69-1.79)  4/1,554 0.52 (0.18-1.54) 0.26 
          
P53+ vs. Controls 36/369 1.00 (reference)  151/1,554 1.04 (0.71-1.55)  13/138 0.79 (0.38-1.65) 0.35 
P53- vs. Controls 96/369 1.00 (reference)  390/1,554 0.96 (0.74-1.24)  21/138 0.56 (0.33-0.95) 0.02 
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; OR, odds ratio; CI, confidence interval 
* P-heterogeneity < 0.05 for comparisons of ORs in each breast cancer subtype versus ER-/PR-, HER2+, Luminal A, or p53+, respectively 
a  Luminal A: ER+ or PR+, HER2-; Luminal B: ER+ or PR+, HER2+; HER2 Expressing: ER-/PR-, HER2+; Triple-negative: ER-/PR-/HER2-  
b Adjusted for age, education, race, and menopausal status  
 
 
 
 
 
 
